openPR Logo
Press release

B Cell Lymphoma Market B Cell Lymphoma Clinical Pipeline Report 2022

07-11-2017 09:50 AM CET | Health & Medicine

Press release from: Kuick Resarch

B Cell Lymphoma Market B Cell Lymphoma Clinical Pipeline Report

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Report Table of Contents

1. Introduction to B Cell Lymphoma
1.1 Outline
1.1.1 Non-Hodgkin’s Lymphoma
1.1.2 Hodgkin’s Lymphoma
1.2 Classification of the B Cell lymphoma
1.2.1 Diffuse Large B Cell Lymphoma
1.2.2 Follicular Lymphoma
1.2.3 Mantle Cell Lymphoma
1.2.4 Burkitt Lymphoma
1.3 Stages of B Cell Lymphoma

2. Role of B Cell Receptor for Lymphoma Development
2.1 Diffuse Large B Cell Lymphoma
2.2 Mantle Cell Lymphoma
2.3 Burkitt Lymphoma

3. Non-Hodgkin Lymphoma Risk Factors
3.1 Overview of Risk Factors
3.1.1 Infections
3.1.2 Weakened Immune System
3.1.3 Exposure to Radiation
3.1.4 Exposure to Chemicals
3.2 Causes of Non-Hodgkin Lymphoma

4. Strategies for B Cell Lymphoma Targeting Therapies
4.1 Current Strategies
4.1.1 Bruton’s Tyrosine Kinase (BTK)
4.1.2 Phosphoinositide 3-Kinase anddelta; (PI3Ks)
4.1.3 Spleen Tyrosine Kinase (SYK)
4.2 Next Generation Strategies for the Vaccine Therapy
4.2.1 Membrane Proteoliposomal Vaccine
4.2.2 Cytotoxic Therapies

5. Diagnosis of B Cell Lymphoma
5.1 Traditional Methods of Detection
5.1.1 Biopsy Method
5.1.2 Flow Cytometry
5.1.3 Molecular Genetic Tests
5.1.4 Positron Emission Tomography (PET) Scan
5.2 New Insights for Diagnosis of B Cell Lymphoma
5.2.1 Genomic Studies in the Diagnosis
5.2.2 Next Generation Sequencing
5.3 Biomarker in B Cell Malignancies
5.3.1 MicroRNA-155
5.3.2 B Cell Markers

6. Approaches for the Treatment B Cell Lymphoma
6.1 Chemotherapy
6.2 Radiation Therapy

7. Targeted Therapy Drugs for B Cell Lymphoma
7.1 Proteasome Inhibitors
7.2 Anti-CD22 Antibody Epratuzumab
7.3 Immunomodulators
7.4 Fostamatinib Disodium (Syk Inhibitor)
7.5 Membrane Target of Rapamycin (mTOR)

8. Global B Cell Lymphoma Market Overview
8.1 Current Scenario
8.2 Prevalence
8.3 B Cell Lymphoma Clinical Pipeline Overview

9. Global B Cell Lymphoma Market Dynamics
9.1 Accelerative Parameters
9.2 Challenges to the Market Growth

10. Global B Cell Lymphoma Market Future Scenario

11. Global B Cell Lymphoma Clinical Pipeline by Company and Phase
11.1 Research
11.2 Preclinical
11.3 Clinical
11.4 Phase-I
11.5 Phase-I/II
11.6 Phase-II
11.7 Phase-II/III
11.8 Phase-III
11.9 Preregistration
11.10 Registered

12. Marketed B Cell Lymphoma Clinical Insight
12.1 Rituximab (MabThera and Rituxan)
12.2 Rituximab Biosimilar (Novex)
12.3 Rituximab Biosimilar (Maball)

13. Competitive Landscape
13.1 Abbott Laboratories
13.2 Biogen Idec
13.3 Celgene Corporation
13.4 Genmab
13.5 Hetero Drugs
13.6 ImmunoGen
13.7 Incyte Corporation
13.8 mAbxience
13.9 Merck
13.10 Millennium Pharmaceuticals
13.11 Ono Pharmaceutical
13.12 Sandoz
13.13 Seattle Genetics
13.14 Xencor

Download Report: https://www.kuickresearch.com/report-global-b-cell-lymphoma-market-and-clinical-pipeline-insight-2022.php

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release B Cell Lymphoma Market B Cell Lymphoma Clinical Pipeline Report 2022 here

News-ID: 618376 • Views: 217

More Releases from Kuick Resarch

Global Antibody Drug Conjugate Market Sales Size Opportunity To Surpass US$ 10 B …
"Novel Cancer Antibody Drug Conjugates to Drive Cancer Therapeutics Market With More Than 290 Cancer Antibodies In Clinical Trials Pipeline Says Kuick Research" "Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026" Report Highlights: • Global Cancer Antibody Drug Conjugate (ADC) Pipeline: 297 Drugs • Marketed Cancer Antibody Drug Conjugate: 9 Drugs • Antibody Drug Conjugate Marketed Opportunity: > US$ 13 Billion By 2026 • Majority of Drug Trials Are For Second Line Therapy
Global Cell Therapy Market Stem Cell Therapy Market Size Sales Growth Clinical T …
Global Cell Therapy Market Size Sales Opportunity To Surpass USD 40 Billion By 2027 Says Kuick Research Report Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027 "Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027" Report Highlights: • Global Cell Therapy Market: > USD 40 Billion By 2027 • Cell Therapy Clinical Trial Insight by Indication, Company and Country • Cell Therapy Price & Product Insight By Region/Country • Clinical
Global Small Molecule Targeted Cancer Drug Market Size Sales To Reach US$ 130 Bi …
"Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" Report Highlights: • Global Small Molecule Cancer Drug Market: > US$ 125 Billion by 2026 • USA Dominates Global Small Molecule Cancer Drug Market: >50% Share • Number of Small Molecule Cancer Drugs In Clinical Trials: >2500 Drugs • Small Molecule Cancer Drugs Dosage, Sales, Price & Patent Insight: 175 Drugs • Small Molecule Drug Insight by Cancer • Clinical Trials Insight
GCC Clinical Trial Market Outlook Insight 2025
"GCC Clinical Trial Market Outlook 2025" Report Highlights: • GCC Clinical Trial Market Opportunity: >US$ 500 Million • GCC Disease Prevalence & Statistics • Saudi Arabia Dominating GCC Clinical Trial Landscape: > 500 Trials • Clinical Trials for Cancer in GCC: > 120 Trials • Guidelines For Conducting Clinical Trials by Country • Ongoing Clinical Trials Insight by Country Download Report: https://www.kuickresearch.com/report-report-report-report-report-report-report-report-gcc-clinical-trial-market-size-number--data-regulation-registration Table of Contents 1. GCC Clinical Market Regional Insights 2. GCC Clinical Trial Market Dynamics 2.1 Driving Forces for GCC Clinical Trial

All 5 Releases


More Releases for Lymphoma

Lymphoma Drugs Market Growth 2019-2024
According to 24 Market Reports study, over the next five years the Lymphoma Drugs market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. Lymphoma is cancer that begins in infection-fighting cells of the immune system, called lymphocytes. These cells are in the lymph nodes, spleen, thymus, bone marrow, and other parts of the
Lymphoblastic Lymphoma Market : Overview and Analysis
Lymphoblastic lymphoma involves both T-lymphocytes and B-lymphocytes, of which 84% to 90% cases of lymphoblastic lymphoma involve T-lymphocytes. Chemotherapy is the preferred choice and first line treatment in cases of lymphoblastic lymphoma, where the regimen is followed for the treatment and includes induction chemotherapy, consolidation chemotherapy, and continuing chemotherapy. Other treatments include radiotherapy which might be given in the brain or spine if lymphoma cells are present or in other
Burkitt Lymphoma Therapeutics Market Key Growth Drivers
Burkitt lymphoma is a form of non-Hodgkin's lymphomas (NHLs) which are a group of blood cancers derived from lymphocytes. Burkitt lymphoma is a rare disease and occurs only in one in every 30-50 people with non-Hodgkin's lymphomas. According to the World Health Organization (WHO), Burkitt lymphomas are of three types, namely, endemic, sporadic and immunodeficiency associated. Endemic NHL is also known as African type and affects African children aged between
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline landscape. Hodgkin disease is a cancer of the lymphatic system. It
Lymphoma Therapeutics Market Report : 2017
Reports And Markets Publish a New Market Research Report On –"Lymphoma Therapeutics Market Report 2017" Access Full Report With Table Of Contents @ https://www.reportsandmarkets.com/reports/united-states-lymphoma-therapeutics-market-report-2017-1541149 In this report, the United States Lymphoma Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into
T Cell Lymphoma Market T Cell Lymphoma Clinical Pipeline Report
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. T-Cell Lymphoma Market Analysis 2. Mechanism of T-Cell Lymphoma Therapeutics 3. T-Cell Lymphoma Drug Market Overview 3.1 Current Market Scenario 3.2 T Cell Lymphoma Clinical Pipeline Overview 4. T-Cell Lymphoma Drug Market Dynamics 4.1 Favorable Market Parameters 4.2 Commercialization Challenges 5. T-Cell Lymphoma Drug Market Future Prospects 6. T-Cell Lymphoma Drug Clinical Pipeline By Company